Study: Zoledronic acid inhibits bone growth

04/25/2013 | AAFP News Now

Researchers found osteoporosis drug zoledronic acid increases levels of a biomarker that inhibits bone formation in postmenopausal women. The study was published in the Journal of Clinical Endocrinology & Metabolism. Lead author Antonino Catalano, M.D., said patients who use zoledronic acid may need other treatments to allow for new bone formation.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA